Masld clinical trials

Explore recruiting masld clinical trials.

Recruiting masld studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Masld trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Czechia, France, Netherlands, Bulgaria, Norway, Austria +9 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

The effect of semaglutide therapy on hepatic fat content and on the acute reponse of liver fat to high-fat load in obese MASLD patients

Czechia

Therapeutic confirmatory (Phase III) EU CTIS Study details

ADVANCE: A Phase III Multi-Centre, Randomised, Double-Blind, Double-Dummy Clinical Trial Comparing Essentiale® Liquid vs. Capsules for MASLD/MASH, Alcoholic Liver Disease, and Chronic Viral Hepatitis B

Bulgaria, Germany, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Dasatinib and quercetin, a combination of senolytics to treat fibrotic non-alcoholic fatty liver disease; The TRUTH study

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

REVERsal to normoglycemia by Treating PREDIABETES: the REVERT-PREDIABETES trial

Denmark

Phase III and phase IV (Integrated) EU CTIS Study details

Impact of Glucagon on Physical Capacity and Metabolism

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Masld trials by city

Masld in Toronto Masld in Vancouver Masld in Montreal Masld in Calgary Masld in Edmonton Masld in Ottawa Masld in Winnipeg Masld in Quebec City Masld in Hamilton Masld in Kitchener Masld in London Masld in Halifax Masld in New York Masld in Los Angeles Masld in Chicago Masld in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease